Email:shdiahds@163.com
Phone:+1-909-839-7620
Fax:+1-909-839-7620
Click here for qusetions for this product!
Product Catalog
Factor VIII (S2194) Antibody
Current Country :
Download PDF Datasheet
Catalogue No : BS1119
| Host | Reactivity | Size | Application | stock | price | cart |
| BS1119 | H,M | 100μg | WB IHC |  |
218.00 |  |
|
Contact information
|
||||||
Product
1 mg/ml in Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.2.
Purification & Purity
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Specificity
Factor VIII (S2194) antibody detects endogenous levels of Factor VIII protein.
Applications (Recommended Dilutions)
WB: 1:500~1:1000 IHC: 1:50~1:200
Western Blot(WB)
Western blot (WB) analysis of. Factor VIII (S2194) antibody in extracts from HuvEc cells.
Storage&Stability
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Background
Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (prothrombin, and Factors X, IX, V, and VIII), which are involved in a blood coagulation cascade that leads to the formation of insoluble fibrin clots and the promotion of platelet aggregation. Coagulation Factor VII (serum prothrombin conversion accelerator, proconvertin, F7, Factor VII) is a 406 amino acid, vitamin K-dependent, single chain serine protease that is synthesized in the liver and circulates as an inactive precursor. Factor IX A, Factor X A, Factor XII A, or thrombin mediated proteolytic cleavage of Factor VII at Arg152-Ile153 generates Factor VII A, an active serine protease composed of a catalytic heavy chain disulfide linked to a light chain, containing 2 EGF-like domains. Mutations at the F7 locus that lead to Factor VII deficiencies are generally asymptomatic or phenotypically uncharacterized, with hemorrhagic diathesis occurring at extremely low levels.